UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 170 filers reported holding UNIQURE NV in Q2 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,630 | +305.9% | 1,137 | +593.3% | 0.00% | – |
| Q2 2023 | $1,880 | -43.1% | 164 | 0.0% | 0.00% | – |
| Q1 2023 | $3,303 | -11.2% | 164 | 0.0% | 0.00% | – |
| Q4 2022 | $3,718 | -7.0% | 164 | -26.8% | 0.00% | – |
| Q3 2022 | $4,000 | +33.3% | 224 | +36.6% | 0.00% | – |
| Q2 2022 | $3,000 | 0.0% | 164 | 0.0% | 0.00% | – |
| Q1 2022 | $3,000 | 0.0% | 164 | 0.0% | 0.00% | – |
| Q4 2021 | $3,000 | -40.0% | 164 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | 0.0% | 164 | 0.0% | 0.00% | – |
| Q2 2021 | $5,000 | -16.7% | 164 | 0.0% | 0.00% | – |
| Q1 2021 | $6,000 | 0.0% | 164 | -1.8% | 0.00% | – |
| Q4 2020 | $6,000 | 0.0% | 167 | +1.8% | 0.00% | – |
| Q3 2020 | $6,000 | -14.3% | 164 | 0.0% | 0.00% | – |
| Q2 2020 | $7,000 | -12.5% | 164 | 0.0% | 0.00% | – |
| Q1 2020 | $8,000 | -33.3% | 164 | 0.0% | 0.00% | – |
| Q4 2019 | $12,000 | – | 164 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |